Compare IMXI & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMXI | PROK |
|---|---|---|
| Founded | 1994 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 469.3M | 416.6M |
| IPO Year | 2016 | 2021 |
| Metric | IMXI | PROK |
|---|---|---|
| Price | $13.03 | $1.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $15.00 | $7.40 |
| AVG Volume (30 Days) | 342.7K | ★ 1.6M |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $319,601,000.00 | $893,000.00 |
| Revenue This Year | $0.83 | N/A |
| Revenue Next Year | $1.49 | N/A |
| P/E Ratio | $666.00 | ★ N/A |
| Revenue Growth | 16.68 | ★ 1075.00 |
| 52 Week Low | $8.58 | $1.48 |
| 52 Week High | $15.95 | $3.55 |
| Indicator | IMXI | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 33.86 | 34.77 |
| Support Level | N/A | N/A |
| Resistance Level | $15.38 | $2.59 |
| Average True Range (ATR) | 0.37 | 0.10 |
| MACD | -0.07 | -0.03 |
| Stochastic Oscillator | 10.47 | 2.54 |
International Money Express Inc is an omnichannel money remittance services company focused on the United States of America to Latin America and the Caribbean corridor, which includes Mexico, Central and South America and the Caribbean. The company offers wire transfer, money order, Foreign exchange, and cash checking services, while the majority of the revenue is derived from wire transfer and money order fees. The firm's business is organized around one reportable segment that provides money remittance services between the U.S. and Canada to Mexico, Guatemala, and other countries in Latin America, Africa, and Asia.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.